SINTX Names Ryan Elmore President to Accelerate SiN Biomaterials Commercialization

SINTX Technologies, Inc. (NASDAQ: SINT) has appointed Ryan Elmore as President, effective March 16, 2026, tasking him with accelerating commercialization and channel expansion for the company’s silicon nitride biomaterial platforms, including SiNERGY™ SiN/PEEK biocomposites and antipathogenic fibrous materials. The Salt Lake City press release was distributed via GlobeNewswire on Feb. 18, 2026.

Eric K. Olson will remain Chairman and Chief Executive Officer but, according to a TradingView capture of an SEC Form 8‑K, will cease serving as President effective March 16, 2026; TradingView also notes an employment agreement effective Feb. 6, 2026. Eric K. Olson said, “Ryan is a proven commercial leader, and his appointment represents an important step as we continue to advance SINTX’s evolution into a platform company,” and “SINTX is uniquely positioned at the intersection of advanced ceramics, polymer composites, and biomaterials. We believe our opportunity may extend well beyond implants. Our priority is to convert our materials science and IP into measurable commercial traction through licensing, strategic partnerships, and expanded partnership engagement.”

The company release and reporting outlets describe Elmore as having “most recently served as Core Business Director at Invibio, a division of Victrex plc” and state he has “more than 15 years of experience in advanced biomaterials and medical device commercialization.” TradingView’s summary of the 8‑K offers a different characterization, describing Elmore as having “20+ years in medical device and life sciences” and listing prior roles including Core Business Director since September 2021 and Global Head of Sales from 2010–2021.

SINTX’s stated mandate for Elmore includes leading commercialization and channel expansion for its SiN biomaterial platforms and expanding adoption of SiNERGY™ SiN/PEEK for next‑generation implants. The company specifically identifies antipathogenic fibrous material applications for sutures, mesh, wound dressings, and other textile-based uses, and lists licensing, strategic partnerships, and partner-driven commercialization as primary revenue channels.

Product development priorities spelled out across the release and aggregators include new product forms and 3D-printable formats such as filament, rod, and sheet, and continued evaluation of patient‑specific 3D‑printed implants. MarketScreener’s company news feed adds context with a Dec. 1 item noting a supply agreement with Evonik to manufacture a silicon nitride‑PEEK compound for AI-assisted, 3D‑printed patient‑specific implants, and earlier items noting a Q3 revenue miss on Nov. 13 and a tranche update on an equity buyback plan on Nov. 12, 2024.

Elmore commented in the company release, “I am excited to join SINTX at a defining moment in its evolution,” and added, “SINTX has built a differentiated platform around silicon nitride biomaterials, supported by deep materials science expertise, a strong intellectual property foundation, and U.S.-based manufacturing. My focus will be to execute a commercial strategy aimed at supporting market engagement across multiple verticals — from SiNERGY™ SiN/PEEK biocomposites for next-generation implants, to antipathogenic fibrous material applications for sutures, mesh, and wound dressings. We believe these technologies have the potential to address meaningful clinical needs, and we intend to build momentum through disciplined execution, quality, and service.”

For investor relations the release reposted by Stocktitan included contact details: 801-839-3502 and IR@sintx.com, and Stocktitan’s distribution showed language options for the wire in English, Arabic, French, German, Italian, Korean, and Spanish. Elmore steps into the role March 16 with a clear commercial mandate to convert SINTX’s materials science and IP into licensing and partner-driven revenue.